Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renagel funding R&D

Executive Summary

The performance of Renagel has "stabilized" in 2003, and the company is forecasting full-year sales of $240 mil.-$250 mil. That is the same size as Genzyme's projected R&D spending for the year, which will primarily involve completing Phase IV trials of Fabrazyme and Aldurazyme and pivotal studies of the Pompe disease therapy Myozyme...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS041714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel